default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Samsung BioLogics violated accounting rules in 2015

기사승인 2018.11.14  16:56:32

공유
default_news_ad2

- The company sudden profits in 2015 after years of losses

The financial regulator on November 14, 2018 ruled that Samsung BioLogics Co. intentionally violated accounting rules in 2015, a decision that could lead to the delisting of the biopharmaceutical firm.

Kim Yong-beom, vice chairman of the Financial Services Commission (FSC), said the FSC referred the case to prosecutors, adding that trading of Samsung BioLogics shares will be halted.

The regulatory probe by the Securities and Futures Commission centers on questions about Samsung BioLogics' sudden profits in 2015 after years of losses. Samsung BioLogics reported a net profit of 1.9 trillion won (US$1.68 billion) that year after changing the method used to calculate the value of its affiliate, Samsung Bioepis Co., which is a joint venture with the U.S.-based Biogen Inc.

Critics have argued that Samsung BioLogics might have inflated the profit ahead of its listing in 2016. (Yonhap)

Shin Jin-seon edt@koeapost.com

<저작권자 © 코리아포스트 무단전재 및 재배포금지>
default_news_ad5
default_side_ad1
default_nd_ad2

인기기사

default_side_ad2

포토

1 2 3
set_P1
default_side_ad3

섹션별 인기기사 및 최근기사

default_side_ad4
default_nd_ad6
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch